Loading clinical trials...
Loading clinical trials...
A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Conditions
Interventions
BMS-986504
Gemcitabine
+2 more
Locations
279
United States
Local Institution - 0142
Phoenix, Arizona, United States
Local Institution - 0365
Tucson, Arizona, United States
Highlands Oncology Group
Springdale, Arkansas, United States
Scripps Green Hospital
La Jolla, California, United States
Local Institution - 0157
San Francisco, California, United States
Local Institution - 0369
Jacksonville, Florida, United States
Start Date
October 23, 2025
Primary Completion Date
May 3, 2029
Completion Date
May 3, 2029
Last Updated
March 31, 2026
NCT02600949
NCT06921928
NCT06423326
NCT07542041
NCT06821997
NCT06904378
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions